Health
BioRestorative Completes Patient Enrollment in Landmark Phase 2 Trial of BRTX-100 for Chronic Lumbar Disc Disease
Largest FDA-authorized Phase 2 cell therapy trial conducted in chronic lumbar disc diseaseThe study has enrolled a total of 99 participants, each of whom was randomized to receive either BRTX-100 or placeboProspective, randomized, double-blind, sham-controlled single-disc study — gold-standard clinical designEnrollment completion strengthens regulatory pathway toward Phase 3 and potential BLA filing MELVILLE, N.Y., Feb. 10, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative
About this update from Biorestorative Therapies, Inc.
[{"type":"image","alt":"BioRestorative Therapies, Inc","displaySize":"","headline":null,"caption":"BioRestorative Therapies, Inc","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":122,"url":"https://media.zenfs.com/en/globenewswire.com/681a8d8fe6df06a5512b4bdd3f27c992"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/XBsy.n130Az83pQRRSvCjg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE3MTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/681a8d8fe6df06a5512b4bdd3f27c992","width":300,"height":122}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Largest FDA-authorized Phase 2 cell therapy trial conducted in chronic lumbar disc disease","length":90,"tagName":"p"}]},{"val":[{"type":"text","content":"The study has enrolled a total of 99 participants, each of whom was randomized to receive either BRTX-100 or placebo","length":116,"tagName":"p"}]},{"val":[{"type":"text","content":"Prospective, randomized, double-blind, sham-controlled single-disc study — gold-standard clinical design","length":104,"tagName":"p"}]},{"val":[{"type":"text","content":"Enrollment completion strengthens regulatory pathway toward Phase 3 and potential BLA filing","length":92,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":402,"olType":false},{"type":"text","content":"MELVILLE, N.Y., Feb. 10, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a late stage clinical regenerative medicine innovator focused on stem cell-based therapies and products, today announced completion of patient enrollment in its Phase 2 clinical trial evaluating the safety and efficacy of BRTX-100 for the treatment of chronic lumbar disc disease (“cLDD”).","length":429,"tagName":"p"},{"type":"text","content":"BRTX-100 is BioRestorative’s lead clinical candidate — an autologous, hypoxically cultured mesenchymal stem cell therapy engineered for delivery into low-oxygen, low-nutrient disc environments.","length":193,"tagName":"p"},{"type":"text","content":"With 99 patients enrolled across 15 leading U.S. clinical sites, the BRTX-100 Phase 2 study represents, the Company believes, the largest Phase 2 cell-therapy trial conducted in cLDD under a Food and Drug Administration (“FDA”) Investigational New Drug (IND) application and ranks among the largest controlled cell-therapy trials in ...